Skip to content
An Initiative of AVAC
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By
Multiple filters can be used at once

Showing results 81 - 90 of 178

Selected Filters:
7 July 2022

Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa

This study compares the effectiveness and cost-effectiveness of providing antiretroviral therapy vs PrEP in South Africa

Financing & Costing

External Link
7 July 2022

Estimating the cost-effectiveness of pre-exposure prophylaxis to reduce HIV-1 and HSV-2 incidence in HIV-serodiscordant couples in South Africa

This study estimates the cost-effectiveness of daily oral PrEP, with a protective effect against the herpes simplex virus as well as HIV, among HIV serodifferent couples in South Africa

Financing & Costing

External Link
7 July 2022

Dapivirine Vaginal Ring for HIV Prevention: Modeling health outcomes, drug resistance and cost‐effectiveness

This paper evaluates the potential epidemiological impact and cost-effectiveness of dapivirine vaginal ring PrEP among 22- to 45-year-old women in KwaZulu-Natal, South Africa.

Financing & Costing, Research

External Link
7 July 2022

Understanding Service Providers’ Knowledge of Oral PrEP and Attitudes Toward Provisionto Populations at Substantial HIV Risk in South Africa

This poster describes the results of a cross-sectional qualitative study, interviewing providers at public, private, and nongovernmental health facilities in South Africa offering PrEP to explore providers’ attitudes toward and experiences delivering PrEP to AGYW.

Research, Service Delivery

Document
7 July 2022

Creating demand for the Dapivirine vaginal ring

This presentation outlines lessons learned from ring clinical trials and oral PrEP programs in Kenya, South Africa, Uganda, and Zimbabwe that can be applied to the development of demand creation strategies.

Demand Creation/Marketing

Document
7 July 2022

Microbicide Trials Network-043 – B-PROTECTED Study

Microbicide Trials Network-043, or B-PROTECTED, is a Phase IIIb open-label study that evaluated the safety and acceptability of the monthly dapivirine ring and daily oral PrEP in women who are breastfeeding, a time of heightened vulnerability for acquiring HIV.

Research

External Link
7 July 2022

Use of the Dapivirine vaginal ring and effect on cervical cytology abnormalities

This study aims to determine if the dapivirine vaginal ring and the ring device alone (flexible silicone matrix polymer) was associated with the development of cervical cytology abnormalities.

Research, Service Delivery

External Link
7 July 2022

Results from the HPTN 083 Trial

The HIV Prevention Trials Network (HPTN) held a community webinar to discuss the preliminary results of HPTN 083, a global randomized, controlled, double-blinded study that compared the safety and efficacy of long-acting injectable cabotegravir (CAB LA) to daily oral tenofovir/emtricitabine (TDF/FTC) (Truvada) for pre-exposure prophylaxis (PrEP) in transgender women and cisgender men who have sex…

Research

External Link
7 July 2022

Results from the HPTN 084 Trial

The HIV Prevention Trials Network (HPTN) hosted a community webinar to discuss the primary results of HPTN 084, a randomized, double-blind controlled trial designed to evaluate the efficacy and safety of long-acting injectable cabotegravir (CAB LA) to prevent the sexual acquisition of HIV in cisgender women in sub-Saharan Africa.

Research

External Link
7 July 2022

Vaginal Ring Acceptability and Related Preferences among Women in Low- and Middle-income Countries: A systematic review and narrative synthesis

The vaginal ring (VR) is a female-initiated drug-delivery platform used for different indications, including HIV pre-exposure prophylaxis (PrEP). This article outlines a systematic review of VR acceptability, values and preferences among women in low- and middle-income countries (LMIC) to inform further investment and/or guidance on VR use for HIV prevention.

Research

External Link